Simplified Model of Linkage and Retention to Care, Using a Mobile Unit and a Same-day Test and Treat Approach Among Excluded Population. (SIMPLIFIED)

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 4, 2022

Primary Completion Date

December 26, 2023

Study Completion Date

June 12, 2024

Conditions
HIV Infections
Interventions
DRUG

Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]

Patients enrolled in the study and accessing the HIV consultation will start treatment with BIKTARVY on the day of enrollment. Medication will be provided by the sponsor and dispensed through the pharmacy service. The drug will be delivered to the patient with a delegated person outside the hospital environment or it will be the patient himself who picks up the medication.

Trial Locations (1)

Unknown

H. Infanta Leonor, Madrid

All Listed Sponsors
lead

Fundacion SEIMC-GESIDA

OTHER